Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program-Reference-Cited by-同舟云学术

Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

Published:2003-10-09 Issue:12 Volume:17 Page:2318-2357
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Gabert J,Beillard E,van der Velden V H J,Bi W,Grimwade D,Pallisgaard N,Barbany G,Cazzaniga G,Cayuela J M,Cavé H,Pane F,Aerts J L E,De Micheli D,Thirion X,Pradel V,González M,Viehmann S,Malec M,Saglio G,van Dongen J J M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2403135.pdf

Reference192 articles.

1. Lowenberg B, Downing JR, Burnett A . Acute myeloid leukemia. N Engl J Med 1999; 341: 1051–1062.

2. Verma A, Stock W . Management of adult acute lymphoblastic leukemia: moving toward a risk-adapted approach. Curr Opin Oncol 2001; 13: 14–20.

3. Appelbaum FR . Perspectives on the future of chronic myeloid leukemia treatment. Semin Hematol 2001; 38: 35–42.

4. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322–2333.

5. Groupe FdCH. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic finding and outcome. A collaborative study of the Groupe Français de Cytogénétique Hématologique. Blood 1996; 87: 3135–3142.

Cited by 1286 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML;Blood;2024-08-15

2. Evaluation of next-generation sequencing for measurable residual disease monitoring in three major fusion transcript subtypes of B-precursor acute lymphoblastic leukaemia;Pathology;2024-08

3. Tailored Digital PCR Follow-Up of Rare Fusion Transcripts after Initial Detection through RNA Sequencing in Hematological Malignancies;The Journal of Molecular Diagnostics;2024-08

4. Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?;Blood Reviews;2024-08

5. SJPedPanel: A Pan-Cancer Gene Panel for Childhood Malignancies to Enhance Cancer Monitoring and Early Detection;Clinical Cancer Research;2024-07-24